Eupraxia Pharmaceuticals Inc. (EPRX) vs Larimar Therapeutics, Inc. (LRMR)
A side-by-side comparison of Eupraxia Pharmaceuticals Inc. and Larimar Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EPRX
Eupraxia Pharmaceuticals Inc.
$7.74HealthcareDelayed quote: Oct 6, 2026, 1:54 PM EDT
LRMR
Larimar Therapeutics, Inc.
$2.80HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — EPRX vs LRMR
growth of $100 · dividends reinvested · last 2yEPRX +162.7% (+62.1%/yr)LRMR -60.7% (-37.3%/yr)EPRX compounded faster over this window
Log scale — wide-divergence pair
EPRX LRMR
EPRX vs LRMR: by the numbers
- •LRMR is the larger company ($291M vs $259M market cap).
Metrics side by side
Valuation
| Metric | EPRX | LRMR |
|---|---|---|
| P/B ratio | 2.55 | 2.28 |
Profitability
| Metric | EPRX | LRMR |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -38.33% | -135.50% |
| ROIC | -43.56% | -136.49% |
Growth (annualized)
| Metric | EPRX | LRMR |
|---|---|---|
| Total return CAGR (5Y) | N/A | -23.91% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.